新余国科2025年中报简析：净利润同比下降39.68%，三费占比上升明显

Financial Performance Summary - The company reported total revenue of 164 million yuan for the first half of 2025, a decrease of 25.18% year-on-year [1] - The net profit attributable to shareholders was 26.35 million yuan, down 39.68% compared to the previous year [1] - The gross margin improved to 48.6%, an increase of 13.72% year-on-year, while the net margin decreased to 16.08%, down 18.51% [1] - Total expenses (selling, administrative, and financial) accounted for 17.64% of total revenue, reflecting a significant increase of 57.63% year-on-year [1] Cash Flow and Investment Activities - The net cash flow from investment activities decreased by 285.74%, primarily due to an increase in cash outflows from investment activities by 19.52 million yuan [3] - The net cash flow from financing activities also declined by 33.85%, with cash outflows increasing by 12.68 million yuan [3] - The net increase in cash and cash equivalents dropped by 92.69%, attributed to reduced cash flow from operating activities and significant declines in both investment and financing cash flows [3] Accounts Receivable and Credit Risk - The accounts receivable situation is concerning, with accounts receivable to profit ratio reaching 248.77% [4] - The company reported a 127.07% increase in credit impairment losses, indicating potential risks in receivables management [3] Historical Performance and Return on Investment - The company's return on invested capital (ROIC) was 12.4% last year, indicating strong capital returns [4] - Historical data shows a median ROIC of 13.9% since the company went public, with the lowest ROIC recorded at 9.12% in 2019 [4]